

# 1. Data Abstraction Tool

## Article information

1. What is the name of this study? (e.g. DART, Physician's Health Study) *Omit if name of study is not provided.*

- DART
- Physician's Health Study
- Maastricht Essential Fatty Acid Birth (MEFAB) Cohort
- The DIAMOND Study (DHA Intake And Measurement Of Neural Development)
- data using DIAMOND study
- POSGRAD
- NUHEAL
- Infant Fish Oil Supplementation Study (IFOS)
- Danish National Birth Cohort
- Groningen LCPUFA study
- DINO (Docosahexaenoic acid for the Improvement in Neurodevelopmental Outcome)
- DOMINO
- INFAT
- BeMIM (Belgrade-Munch Infant Milk Trial)
- GINI
- The Docosahexaenoic Acid to Optimise Mother Infant Outcome (DOMInO)
- Childhood Asthma Prevention Study
- Salmon in Pregnancy Study (SiPS)

### Other study names

## 2. Study Design

- Trial: Randomized Parallel (Omega-3 vs. Control; Omega-3 XX vs. X)
- Trial: Randomized Cross-over

- Trial: Randomized Factorial Design
- Observational: Prospective, longitudinal, comparative study
- Observational: Nested Case Control

**Other**

**Clear Response**

**3. Funding source**

- Industry funded
- Government funded
- Some authors employed by industry (companies that make the supplements)
- Funding or affiliations not reported
- Multiple foundations and Societies
- None of the authors had any personal or financial conflicts of interest
- Trade group funded
- March of Dimes
- Manufacturer supplied product
- Some authors serve on scientific advisory boards for corporations

**Other funding source**

**4. Country in which study conducted (where subjects live)** *Note that this might be different than the countries where the authors are based. Select "NR (not reported)" if it's truly unclear.*

- US
- Canada
- Denmark
- Finland
- Germany
- Greece
- Italy

- Japan
- Netherlands
- Norway
- Sweden
- UK
- NR (not reported)
- Mexico
- Australia
- Taiwan
- Spain
- Hungary
- Turkey
- Bangladesh
- Thailand
- Serbia
- Multie-center study in hospitals of 11 countries in Europe

#### Other

##### 5. Study Population

- Healthy infants or children
- Preterm infants
- Healthy pregnant women
- Postpartum women
- Breast-feeding women
- Low birth weight infants

- Pregnant mothers with allergies and their offspring
- Pregnant women whose unborn children were at high risk of developing asthma
- children with family history of allergy

**Other**

**6. Inclusion criteria as defined in study**

**7. Exclusion criteria**

**II. Participant Information**

**1. Sample size**

| <b>Pregnant</b>  | <b>Lactating mothers</b>   | <b>Mothers</b>   | <b>Infants</b>   |
|--|--|--|--|
| <input type="checkbox"/> #<br>Enrolled/Rand<br>omized                  | <input type="checkbox"/> #<br>Enrolled/Rand<br>omized                  | <input type="checkbox"/> #<br>Enrolled/Rand<br>omized                  | <input type="checkbox"/> #<br>Enrolled/Rand<br>omized                  |
| <input type="checkbox"/> # of<br>withdrawals                           | <input type="checkbox"/> # of<br>withdrawals                           | <input type="checkbox"/> # of<br>withdrawals                           | <input type="checkbox"/> # of<br>withdrawals                           |
| <input type="checkbox"/> # of<br>completers<br>(largest follow-<br>up) | <input type="checkbox"/> # of<br>completers<br>(largest follow-<br>up) | <input type="checkbox"/> # of<br>completers<br>(largest follow-<br>up) | <input type="checkbox"/> # of<br>completers<br>(largest follow-<br>up) |

**2. Age at baseline**

| <b>Mean age (Pregnant)</b>           | <b>Mean age (Lactating mothers)</b>           | <b>Mean age (Mothers)</b>           | <b>Mean age (Infants)</b>           |
|--------------------------------------|---|-------------------------------------|-------------------------------------|
|                                      |   |                                     |                                     |
| <b>Standard Deviation (Pregnant)</b> | <b>Standard Deviation (Lactating mothers)</b> | <b>Standard Deviation (Mothers)</b> | <b>Standard Deviation (Infants)</b> |

|                             |                                      |                            |                            |
|-----------------------------|--------------------------------------|----------------------------|----------------------------|
|                             |                                      |                            |                            |
| <b>Age range (Pregnant)</b> | <b>Age range (Lactating mothers)</b> | <b>Age range (Mothers)</b> | <b>Age range (infants)</b> |
|                             |                                      |                            |                            |

**3. Race/Ethnicity (Mother)**

- White/European (specify %)
- Black/African American/etc. (specify %)
- Asian (specify %)
- Hispanic (specify %)
- Inuit/Eskimo (specify %)
- NR (specify %)
- varied by study site and experimental group (specify %)
- Minority (specify %)
- Other
- non black
- Puerto Rican/Latino
- Native Hawaiian or other pacific ethnicity

**Other**

**4. Race/Ethnicity (Infant)**

- White/European (specify %)
- Black/African American/etc. (specify %)
- Asian (specify %)

- Hispanic (specify %)
- Inuit/Eskimo (specify %)
- Not reported (specify %)
- varied by study site and experimental groups (specify %)
- Non-white

**Other**

5. Is baseline biomarker information reported?

- Yes  No **Clear Response**

6. Is baseline Omega-3 intake reported?

- Yes  No **Clear Response**

**III. Intervention information [if observational study, please stop here]**

|  | Pregnant  | Lactating mothers                                       | Mothers   | Infants   |
|--|---|---|---|---|
| <b>Start time of intervention</b>        | <input style="width: 100%; height: 15px;" type="text"/> | <input style="width: 100%; height: 15px;" type="text"/> | <input style="width: 100%; height: 15px;" type="text"/> | <input style="width: 100%; height: 15px;" type="text"/> |
| <b>Length (duration) of intervention</b> | <input style="width: 100%; height: 15px;" type="text"/> | <input style="width: 100%; height: 15px;" type="text"/> | <input style="width: 100%; height: 15px;" type="text"/> | <input style="width: 100%; height: 15px;" type="text"/> |
| <b>Longest follow-up time</b>            | <input style="width: 100%; height: 15px;" type="text"/> | <input style="width: 100%; height: 15px;" type="text"/> | <input style="width: 100%; height: 15px;" type="text"/> | <input style="width: 100%; height: 15px;" type="text"/> |

**V. Arms**

**How to fill out this section:**

For controlled trials, Arm 1 should be the placebo/control group or lowest dose of intervention.

1. How many arms are there?

Arm 1:

- Name
- Description

**RCT: Arm 1 (placebo or other control)**

- Brand name (if applicable)
- Manufacturer (specify)
- Purity data (specify)
- Presence of other potentially active ingredients (e.g., arachidonic acid, vitamin E) (specify)

Storage conditions or other efforts to preserve product viability) (specify)

n-3 composition (e.g., grams or percent EPA, DHA per capsule) (specify)

Dose per day (e.g., 1 1gm capsule, twice a day) (specify)

If placebo, how was blinding achieved? (specify)

Maternal conditions

Infant conditions

**Arm 2:**

Name

Description

**RCT: Arm 2 (placebo or other control)**

Brand name (if applicable)

Manufacturer (specify)

Purity data (specify)

Presence of other potentially active ingredients (e.g., arachidonic acid, vitamin E) (specify)

Storage conditions or other efforts to preserve product viability) (specify)

n-3 composition (e.g., grams or percent EPA, DHA per capsule) (specify)

Dose per day (e.g., 1 1gm capsule, twice a day) (specify)

If placebo, how was blinding achieved? (specify)

Maternal conditions

Infant conditions

**Arm 3:**

Name

Description

**RCT: Arm 3 (placebo or other control)**

Brand name (if applicable)

Manufacturer (specify)

- Purity data (specify)
- Presence of other potentially active ingredients (e.g., arachidonic acid, vitamin E) (specify)
- Storage conditions or other efforts to preserve product viability) (specify)
- n-3 composition (e.g., grams or percent EPA, DHA per capsule) (specify)
- Dose per day (e.g., 1 1gm capsule, twice a day) (specify)
- If placebo, how was blinding achieved? (specify)
- Maternal conditions
- Infant conditions

**Arm 4:**

- Name
- Description

**RCT: Arm 4 (placebo or other control)**

- Brand name (if applicable)
- Manufacturer (specify)
- Purity data (specify)
- Presence of other potentially active ingredients (e.g., arachidonic acid, vitamin E) (specify)
- Storage conditions or other efforts to preserve product viability) (specify)
- n-3 composition (e.g., grams or percent EPA, DHA per capsule) (specify)
- Dose per day (e.g., 1 1gm capsule, twice a day) (specify)
- If placebo, how was blinding achieved? (specify)
- Maternal conditions
- Infant conditions

**Arm 5:**

- Name
- Description

**RCT: Arm 5 (placebo or other control)**



- Brand name (if applicable)
- Manufacturer (specify)
- Purity data (specify)
- Presence of other potentially active ingredients (e.g., arachidonic acid, vitamin E) (specify)
- Storage conditions or other efforts to preserve product viability) (specify)
- n-3 composition (e.g., grams or percent EPA, DHA per capsule) (specify)
- Dose per day (e.g., 1 1gm capsule, twice a day) (specify)
- If placebo, how was blinding achieved? (specify)
- Maternal conditions
- Infant conditions

**Please indicate if there are any references from the studies reference list that we should pull (indicate the reference number from the article)**

**Arm 6:**

- Name
- Description

**RCT: Arm 6 (placebo or other control)**

- Brand name (if applicable)
- Manufacturer (specify)
- Purity data (specify)
- Presence of other potentially active ingredients (e.g., arachidonic acid, vitamin E) (specify)
- Storage conditions or other efforts to preserve product viability) (specify)
- n-3 composition (e.g., grams or percent EPA, DHA per capsule) (specify)
- Dose per day (e.g., 1 1gm capsule, twice a day) (specify)
- If placebo, how was blinding achieved? (specify)

Maternal conditions

Infant conditions

**Arm 7:**

Name

Description

**RCT: Arm 7 (placebo or other control)**

Brand name (if applicable)

Manufacturer (specify)

Purity data (specify)

Presence of other potentially active ingredients (e.g., arachidonic acid, vitamin E) (specify)

Storage conditions or other efforts to preserve product viability) (specify)

n-3 composition (e.g., grams or percent EPA, DHA per capsule) (specify)

Dose per day (e.g., 1 1gm capsule, twice a day) (specify)

If placebo, how was blinding achieved? (specify)

Maternal conditions

Infant conditions